Stem cell transplantation for treatment of sickle cell disease: Bone marrow versus cord blood transplants

Thompson, Lisa; Ceja, Maria Estela; Yang, Sonal Patel

doi:10.2146/ajhp110308

Cited by 13 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A variety of allo-HCT types may be distinguished based on different criteria: the degree of identity between donor and recipient according to Human Leucocyte Antigen (HLA)-typing (e.g., matched sibling donor, matched unrelated donor, haploidentical donor), conditioning regimen (myeloablative vs. non-myeloablative), source of stem cells (bone marrow, PBSC, cord blood), and type of GVHD prophylaxis (in vitro or in vivo T-cell depletion, cyclophosphamide-based, tacrolimus-methotrexate based, and others) [ 17 , 18 , 19 ]. Different kinds of allo-HCT have distinct risks and indications that are beyond the scope of this summary.…”

Section: Discussionmentioning

confidence: 99%

Coccidioidomycosis in Allogeneic Stem Cell Transplant Recipients: Case Series and Review of the Literature

Saling

Gea‐Banacloche

Trickett

et al. 2021

JoF

View full text Add to dashboard Cite

Coccidioides is an endemic fungus of the Southwest United States that causes the disease coccidioidomycosis. Immunocompromised persons are at increased risk for severe infection and dissemination. One such population is allogeneic bone marrow transplant (allo-HCT) recipients, but accounts of coccidioidal infection in these patients have rarely been documented. We present two cases of Coccidioides in allo-HCT recipients with good outcomes: one patient who developed pulmonary coccidioidomycosis in the late post-engraftment phase and another with known controlled disseminated infection at the time of transplant. A review of the literature identified 19 allo-HCT recipients with coccidioidomycosis. Due to the limited published literature, no guidelines have yet been established regarding optimal prophylaxis and treatment of Coccidioides infection in allo-HCT recipients. Candidates for transplantation should undergo a rigorous pre-transplant assessment to identify evidence of prior or active coccidioidomycosis. In our experience, patients who visit or live in Coccidioides-endemic areas should receive primary prophylaxis for at least the first 100 days post-transplant, and duration should be extended as long as the patient remains on immunosuppression. Those with prior infection should receive secondary prophylaxis while immunosuppressed. Patients with active infection should have treatment and stabilization of infection and continue anti-fungal treatment through immunosuppression.

show abstract

Section: Discussionmentioning

confidence: 99%

Coccidioidomycosis in Allogeneic Stem Cell Transplant Recipients: Case Series and Review of the Literature

Saling

Gea‐Banacloche

Trickett

et al. 2021

JoF

View full text Add to dashboard Cite

show abstract

“…In the African continent, the prevalence of heterozygous subjects is 1 in 4 persons [3]. Being a genetic predisposition, there is no known cure for sickle cell disorder except for the immunologically-invasive treatment by stem cell transplant from bone marrow or cord blood [4]. Sickle cell trait among African descents is associated with natural selective pressures for survival where protective adaptive mechanisms against malaria have been recorded for individuals with the sickle cell trait.…”

Section: Sickle Cell Epidemiologymentioning

confidence: 99%

Sickle Cell Sperm Selection with Hb-S Mab: A Future Application for Intracytoplasmic Genotypically Selected Sperm Injection (IGSI)

Adenmosun¹,

Asghar²,

Kumi-Diaka³

2017

Arch Clin Microbiol

View full text Add to dashboard Cite

There is no clear scientific consensus on the possibility of characterizing sperm cells based on the expression profile of the Hbb gene which codes for hemoglobin. Sickle cell births on the other hand is being facilitated by the union of heterozygous carriers whose genetics predispose them to a twenty-five per cent chance of birthing a sickle cell child. Current conventional assisted conception procedures such as IVF/PGD are expensive and ethically controversial. This short research review therefore suggests the possibility of being able to further characterize sickle cell sperms with specific sickle cell hemoglobin monoclonal antibodies (Hb-S Mab). This may also have a future application in being able to select sperm cells for micro-injection IVF procedures.

show abstract

“…24 These bacteria can cause serious illness in young children in as little as 24 hours. The patient's spleen may have been removed or be unable to fi lter encapsulated bacteria such as Streptococcus pneumonia and Haemophilus infl uenzae from the bloodstream.…”

Section: Diagnostic Testsmentioning

confidence: 99%

Sickle cell disease

Apanah

Rizzolo²

2013

Journal of the American Academy of Physician Assistants

View full text Add to dashboard Cite

show abstract

Stem cell transplantation for treatment of sickle cell disease: Bone marrow versus cord blood transplants

Cited by 13 publications

References 31 publications

Coccidioidomycosis in Allogeneic Stem Cell Transplant Recipients: Case Series and Review of the Literature

Coccidioidomycosis in Allogeneic Stem Cell Transplant Recipients: Case Series and Review of the Literature

Sickle Cell Sperm Selection with Hb-S Mab: A Future Application for Intracytoplasmic Genotypically Selected Sperm Injection (IGSI)

Sickle cell disease

Contact Info

Product

Resources

About